Study Shows Safety of BioPharmX Topical Formulation

Research suggests BPX-01 topical minocycline could be more effective in treatment of acne than other topical treatments

MENLO PARK, Calif., Dec. 11, 2015  -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company, announced today that research being presented at ASCB 2015 in San Diego shows its unique formulation of minocycline known as BPX-01 may offer a breakthrough in acne treatment because it can safely deliver the antibiotic to the layer of skin where the condition develops.

Study findings will be presented Monday afternoon at the annual gathering of the American Society of Cell Biology.

The Traders Podcast with Rob Booker

Good morning Traders Podcast listeners and welcome to Episode 502 where your host Rob Booker commits to telling more stories to teach principles about trading. He shares a story about his ups and downs as they relate to this time of year. Financially, it is an awfully tricky time of the year to trade. Listen in to make sure you have a game plan for December. Thanks for listening!

[ Listen to The Podcast ]

ProMetic's plasminogen demonstrates rapid therapeutic response in second clinical case

• Second case of broncho-tracheal blockage and multiple organ lesions shows immediate benefit
• Established dose regimen supports acute treatment use in both pediatric and adult patients
• Safety and tolerability confirmed by phase I trial results 
• Significant clinical improvement observed with both acute and chronic lesions
• Safety, pharmacokinetic & clinical data presented at the American Society of Hematology annual conference in Orlando, Florida (ASH 2015)

LAVAL, QC, Dec. 7, 2015  - ProMetic Life Sciences Inc. (TSX:PLI.TO - N) (OTCQX:PFSCF) ("ProMetic" or the "Corporation") announced today new data from its plasma-derived plasminogen replacement therapy Phase I clinical trial for the treatment of Congenital Plasminogen Deficiency ("CPD"). The results from the two cohorts of patients enrolled in the Phase I trial confirm that ProMetic's plasminogen replacement therapy is safe, well tolerated and without any related serious adverse events. Moreover, there were no plasminogen antibodies detected and the results confirm the established therapeutic dose of 6 mg/kg.

Avago Technologies Limited Announces Fourth Quarter and Fiscal Year 2015 Financial Results

• Quarterly GAAP gross margin of 54 percent; Quarterly non-GAAP gross margin from continuing operations of 62 percent
• Quarterly GAAP diluted EPS of $1.49; Quarterly non-GAAP diluted EPS from continuing operations of $2.51

SAN JOSE, Calif., and SINGAPORE, Dec. 02, 2015  -- Avago Technologies Limited ( AVGO ), a leading semiconductor device supplier to the wireless, enterprise storage, wired, and industrial end markets, today reported financial results for the fourth fiscal quarter and fiscal year ended November 1, 2015, and provided guidance for the first quarter of its fiscal year 2016.